Nicole O. Williams, MD, discusses the role of PI3K inhibitors in hormone receptor–positive, HER2-negative breast cancer.
Nicole O. Williams, MD
Advertisement
Articles by Nicole O. Williams, MD
Nicole O. Williams, MD, discusses treatment considerations for selecting between CDK4/6 inhibitors in hormone receptor–positive, HER2-negative breast cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
CELMoDs and Bispecifics Break Through Across Lymphomas and Leukemias at EHA 2026
3
FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer
4
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026
5